ReviewCell death discovery2026
The emerging Nexus of STING signaling and ferroptosis: from mechanisms to therapeutic opportunities.
Review in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The mitochondrial DNA-cGAS-STING axis in colorectal cancer: a focused review of context-dependent roles and therapeutic opportunities.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, a cornerstone of innate immunity, and ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, have traditionally been studied as distinct entities. However, emerging evidence reveals a complex and bidirectional crosstalk between these two pathways with profound implications for disease pathogenesis and therapy. This review systematically synthesizes the current understanding of the multifaceted interactions between the cGAS-STING pathway and ferroptosis. We detail the mechanisms by which STING signaling promotes ferroptosis through iron metabolism (e.g., NCOA4-mediated ferritinophagy), lipid peroxidation (e.g., via ACSL4 interaction), and GPX4 autophagic degradation. Conversely, we explore how ferroptosis, through mitochondrial DNA release and lipid peroxidation products, can activate the cGAS-STING pathway, amplifying immune and inflammatory responses. A novel, non-canonical role for mitochondrially-localized cGAS in suppressing ferroptosis independent of STING is also highlighted, adding a layer of complexity to this interplay. We consolidate evidence of this crosstalk across a spectrum of diseases, including cancer, infectious diseases, neurodegenerative disorders, and ischemia-reperfusion injuries. In cancer, leveraging this interplay-particularly by inducing ferroptosis to activate STING-dependent anti-tumor immunity-presents promising therapeutic strategies. In contrast, for inflammatory and organ injuries, concurrent inhibition of both pathways may mitigate damage. This review underscores the STING-ferroptosis axis as a critical regulatory node and a promising frontier for developing novel therapeutic interventions across diverse human diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.